GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
UK-based genetic medicine developer Orchard Therapeutics has filed to raise approximately $173m in an initial public offering that will allow corporates GlaxoSmithKline (GSK), Medison and Sphera Global Health Care to exit.
Orchard is developing gene therapy treatments for serious and life-threatening rare diseases, focusing on neurometabolic disorders, immune deficiencies and hemoglobinopathies.
The IPO proceeds will support registrational trials for a range of drug candidates including five lentiviral product candidates currently in clinical development.
The company has raised more than…
